Gordan Srkalovic Srkalovic

Prof. Dr. Gordan Srkalovic Srkalovic


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Blood Advances
Verified
Journal Article
Open access
SPSheila K. Pierson
Sheila K. Pierson
JBJoshua D. Brandstadter
Joshua D. Brandstadter
DTDrew Torigian
Drew Torigian
ABAdam Bagg
Adam Bagg
MLMary Jo Lechowicz
Mary Jo Lechowicz
DFDavid C. Fajgenbaum
David C. Fajgenbaum
Castleman disease (CD) describes a group of rare lymphoproliferative disorders that exhibit a wide range of symptomatology and degree of lymphadenopathy, particularly across the 2 forms of CD with unknown etiology, unicentric CD (UCD), and human herpesvirus-8–negative/idiopathic multicentric CD (iMCD). Whereas UCD cases typically present with localized lymphadenopathy and mild symptoms, iMCD involves multicentric lymphadenopathy and cytokine storm–driven symptoms with 3 recognized clinical phenotypes. Increasingly, there are anecdotal reports of cases that do not fit into this framework, but these cases have not been systematically described. Herein, we use the ACCELERATE natural history registry to characterize the spectrum of CD based on disease features, symptomatology, and severity. Our results characterize a cohort of 179 CD cases, which were reviewed and confirmed by an expert panel of clinicians and hematopathologists. We show that patients with CD present on a continuous spectrum of clinical phenotypes, and we describe oligocentric CD (OligoCD), an intermediate phenotype that does not fit the criteria for UCD or iMCD. These cases tend to have “oligocentric” lymphadenopathy (median [interquartile range] regions of lymphadenopathy, 3.0 [2.0-4.0]) in a regional pattern and exhibit a mild clinical phenotype that is more similar to UCD than iMCD. We also show that patients with OligoCD are inconsistently categorized as UCD vs iMCD, highlighting the need for this characterization. Future data collected through ACCELERATE may further elucidate the natural history and risk profile of these patients.

14 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
GSGordan Srkalovic Srkalovic
Gordan Srkalovic Srkalovic
SNSally Nijim
Sally Nijim
MSMaya Blanka Srkalovic
Maya Blanka Srkalovic
DFDavid Fajgenbaum
David Fajgenbaum
TAFRO (thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (F/R), renal failure (R), and organomegaly (O)) is a heterogeneous clinical subtype of idiopathic multicentric Castleman disease (iMCD) associated with a significantly poorer prognosis than other subtypes of iMCD. TAFRO symptomatology can also be seen in pathological contexts outside of iMCD, but it is unclear if those cases should be considered representative of a different disease entity or simply a severe presentation of other infectious, malignant, and rheumatological diseases. While interleukin-6 (IL-6) is an established driver of iMCD-TAFRO pathogenesis in a subset of patients, the etiology is unknown. Recent case reports and literature reviews on TAFRO patients suggest that vascular endothelial growth factor (VEGF), and the interplay of VEGF and IL-6 in concert, rather than IL-6 as a single cytokine, may be drivers for iMCD-TAFRO pathophysiology, especially renal injury. In this review, we discuss the possible role of VEGF in the pathophysiology and clinical manifestations of iMCD-TAFRO. In particular, VEGF may be involved in iMCD-TAFRO pathology through its ability to activate RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways. Further elucidating a role for the VEGF-IL-6 axis and additional disease drivers may shed light on therapeutic options for the treatment of TAFRO patients who do not respond to, or otherwise relapse following, treatment with IL-6 targeting drugs. This review investigates the potential role of VEGF in the pathophysiology of iMCD-TAFRO and the potential for targeting related signaling pathways in the future.

19 November 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SDSteven R. Deitcher
Steven R. Deitcher
TCToni Choueiri
Toni Choueiri
GSGordan Srkalovic Srkalovic
Gordan Srkalovic Srkalovic
MHMohamad A. Hussein
Mohamad A. Hussein
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

4 May 2022 in British Journal of Haematology
Verified
Journal Article
Open access
DFDavid C. Fajgenbaum
David C. Fajgenbaum
SPSheila K. Pierson
Sheila K. Pierson
KKKaran Kanhai
Karan Kanhai
ABAdam Bagg
Adam Bagg
DADaisy Alapat
Daisy Alapat
ATAccelerate Registry Team
Accelerate Registry Team
Summary: Castleman disease (CD) describes a group of rare, potentially fatal lymphoproliferative disorders. To determine factors associated with mortality in CD, we analysed data from deceased patients in the ACCELERATE registry and compared them with matched controls. We analysed demographic, treatment and laboratory data from all deceased CD patients, matched controls and a subgroup of idiopathic multicentric Castleman disease (iMCD) patients. Of the 140 patients in ACCELERATE with a confirmed CD diagnosis, 10 had died. There were 72 patients with confirmed iMCD; six were deceased. The deceased CD cohort had more hospitalisations per year, higher overall hospitalisations and more days hospitalised per month, and received more treatment regimens per year than the matched‐control group. Analysis of laboratory values showed a significantly decreased absolute lymphocyte count at months 3 and 6 in the deceased cohort compared with controls. Among iMCD patients, there was a higher proportion of iMCD‐TAFRO (thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction and organomegaly) cases in the deceased group. The deceased iMCD group had significantly lower immunoglobulin M, international normalised ratio and platelet count. These data demonstrate that there may be differences between patients who have fatal and non‐fatal outcomes, and provide preliminary suggestions for parameters to evaluate further.

4 September 2009 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
BOB Olsen
B Olsen
GSGordan Srkalovic Srkalovic
Gordan Srkalovic Srkalovic
Marcia HallMarcia Hall
Marcia Hall
EME McPhail
E McPhail
This report describes an unusual case of cyclin D1 expression by an otherwise typical follicular lymphoma, of low histological grade. BCL2–IGH and CCND1–IGH fusions were identified by interphase fluorescence in situ hybridisation.

20 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
GBG. Thomas Budd
G. Thomas Budd
WBWilliam E. Barlow
William E. Barlow
HMHalle C.F. Moore
Halle C.F. Moore
THTimothy J. Hobday
Timothy J. Hobday
JSJames A. Stewart
James A. Stewart
GHGabriel N. Hortobagyi
Gabriel N. Hortobagyi
CRA1008 The full, final text of this abstract will be available at asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.